Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Formulation CDMO Services Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Small Molecule CDMO
1.2.3 Macro-molecular CDMO
1.3 Market by Application
1.3.1 Global Formulation CDMO Services Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Clinical Application
1.3.3 Commercial Production
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Formulation CDMO Services Market Perspective (2018-2033)
2.2 Formulation CDMO Services Growth Trends by Region
2.2.1 Global Formulation CDMO Services Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Formulation CDMO Services Historic Market Size by Region (2018-2023)
2.2.3 Formulation CDMO Services Forecasted Market Size by Region (2024-2033)
2.3 Formulation CDMO Services Market Dynamics
2.3.1 Formulation CDMO Services Industry Trends
2.3.2 Formulation CDMO Services Market Drivers
2.3.3 Formulation CDMO Services Market Challenges
2.3.4 Formulation CDMO Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Formulation CDMO Services Players by Revenue
3.1.1 Global Top Formulation CDMO Services Players by Revenue (2018-2023)
3.1.2 Global Formulation CDMO Services Revenue Market Share by Players (2018-2023)
3.2 Global Formulation CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Formulation CDMO Services Revenue
3.4 Global Formulation CDMO Services Market Concentration Ratio
3.4.1 Global Formulation CDMO Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Formulation CDMO Services Revenue in 2022
3.5 Formulation CDMO Services Key Players Head office and Area Served
3.6 Key Players Formulation CDMO Services Product Solution and Service
3.7 Date of Enter into Formulation CDMO Services Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Formulation CDMO Services Breakdown Data by Type
4.1 Global Formulation CDMO Services Historic Market Size by Type (2018-2023)
4.2 Global Formulation CDMO Services Forecasted Market Size by Type (2024-2033)
5 Formulation CDMO Services Breakdown Data by Application
5.1 Global Formulation CDMO Services Historic Market Size by Application (2018-2023)
5.2 Global Formulation CDMO Services Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Formulation CDMO Services Market Size (2018-2033)
6.2 North America Formulation CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Formulation CDMO Services Market Size by Country (2018-2023)
6.4 North America Formulation CDMO Services Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Formulation CDMO Services Market Size (2018-2033)
7.2 Europe Formulation CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Formulation CDMO Services Market Size by Country (2018-2023)
7.4 Europe Formulation CDMO Services Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Formulation CDMO Services Market Size (2018-2033)
8.2 Asia-Pacific Formulation CDMO Services Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Formulation CDMO Services Market Size by Region (2018-2023)
8.4 Asia-Pacific Formulation CDMO Services Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Formulation CDMO Services Market Size (2018-2033)
9.2 Latin America Formulation CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Formulation CDMO Services Market Size by Country (2018-2023)
9.4 Latin America Formulation CDMO Services Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Formulation CDMO Services Market Size (2018-2033)
10.2 Middle East & Africa Formulation CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Formulation CDMO Services Market Size by Country (2018-2023)
10.4 Middle East & Africa Formulation CDMO Services Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Medicilon
11.1.1 Medicilon Company Detail
11.1.2 Medicilon Business Overview
11.1.3 Medicilon Formulation CDMO Services Introduction
11.1.4 Medicilon Revenue in Formulation CDMO Services Business (2018-2023)
11.1.5 Medicilon Recent Development
11.2 Gliead
11.2.1 Gliead Company Detail
11.2.2 Gliead Business Overview
11.2.3 Gliead Formulation CDMO Services Introduction
11.2.4 Gliead Revenue in Formulation CDMO Services Business (2018-2023)
11.2.5 Gliead Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Detail
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Formulation CDMO Services Introduction
11.3.4 Boehringer Ingelheim Revenue in Formulation CDMO Services Business (2018-2023)
11.3.5 Boehringer Ingelheim Recent Development
11.4 Vertex
11.4.1 Vertex Company Detail
11.4.2 Vertex Business Overview
11.4.3 Vertex Formulation CDMO Services Introduction
11.4.4 Vertex Revenue in Formulation CDMO Services Business (2018-2023)
11.4.5 Vertex Recent Development
11.5 Mirati Therapeutics
11.5.1 Mirati Therapeutics Company Detail
11.5.2 Mirati Therapeutics Business Overview
11.5.3 Mirati Therapeutics Formulation CDMO Services Introduction
11.5.4 Mirati Therapeutics Revenue in Formulation CDMO Services Business (2018-2023)
11.5.5 Mirati Therapeutics Recent Development
11.6 AMPAC
11.6.1 AMPAC Company Detail
11.6.2 AMPAC Business Overview
11.6.3 AMPAC Formulation CDMO Services Introduction
11.6.4 AMPAC Revenue in Formulation CDMO Services Business (2018-2023)
11.6.5 AMPAC Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Formulation CDMO Services Introduction
11.7.4 Pfizer Revenue in Formulation CDMO Services Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 Polypeptide
11.8.1 Polypeptide Company Detail
11.8.2 Polypeptide Business Overview
11.8.3 Polypeptide Formulation CDMO Services Introduction
11.8.4 Polypeptide Revenue in Formulation CDMO Services Business (2018-2023)
11.8.5 Polypeptide Recent Development
11.9 Bachem
11.9.1 Bachem Company Detail
11.9.2 Bachem Business Overview
11.9.3 Bachem Formulation CDMO Services Introduction
11.9.4 Bachem Revenue in Formulation CDMO Services Business (2018-2023)
11.9.5 Bachem Recent Development
11.10 Merck
11.10.1 Merck Company Detail
11.10.2 Merck Business Overview
11.10.3 Merck Formulation CDMO Services Introduction
11.10.4 Merck Revenue in Formulation CDMO Services Business (2018-2023)
11.10.5 Merck Recent Development
11.11 Asymchem
11.11.1 Asymchem Company Detail
11.11.2 Asymchem Business Overview
11.11.3 Asymchem Formulation CDMO Services Introduction
11.11.4 Asymchem Revenue in Formulation CDMO Services Business (2018-2023)
11.11.5 Asymchem Recent Development
11.12 Zhejiang Jiuzhou Pharmaceutical
11.12.1 Zhejiang Jiuzhou Pharmaceutical Company Detail
11.12.2 Zhejiang Jiuzhou Pharmaceutical Business Overview
11.12.3 Zhejiang Jiuzhou Pharmaceutical Formulation CDMO Services Introduction
11.12.4 Zhejiang Jiuzhou Pharmaceutical Revenue in Formulation CDMO Services Business (2018-2023)
11.12.5 Zhejiang Jiuzhou Pharmaceutical Recent Development
11.13 Sinopep
11.13.1 Sinopep Company Detail
11.13.2 Sinopep Business Overview
11.13.3 Sinopep Formulation CDMO Services Introduction
11.13.4 Sinopep Revenue in Formulation CDMO Services Business (2018-2023)
11.13.5 Sinopep Recent Development
11.14 Frontier Biotechnologies
11.14.1 Frontier Biotechnologies Company Detail
11.14.2 Frontier Biotechnologies Business Overview
11.14.3 Frontier Biotechnologies Formulation CDMO Services Introduction
11.14.4 Frontier Biotechnologies Revenue in Formulation CDMO Services Business (2018-2023)
11.14.5 Frontier Biotechnologies Recent Development
11.15 JYMed
11.15.1 JYMed Company Detail
11.15.2 JYMed Business Overview
11.15.3 JYMed Formulation CDMO Services Introduction
11.15.4 JYMed Revenue in Formulation CDMO Services Business (2018-2023)
11.15.5 JYMed Recent Development
11.16 Chengdu Shengnuo Biotechnology
11.16.1 Chengdu Shengnuo Biotechnology Company Detail
11.16.2 Chengdu Shengnuo Biotechnology Business Overview
11.16.3 Chengdu Shengnuo Biotechnology Formulation CDMO Services Introduction
11.16.4 Chengdu Shengnuo Biotechnology Revenue in Formulation CDMO Services Business (2018-2023)
11.16.5 Chengdu Shengnuo Biotechnology Recent Development
11.17 Shanghai Soho-Yiming Pharmaceuticals
11.17.1 Shanghai Soho-Yiming Pharmaceuticals Company Detail
11.17.2 Shanghai Soho-Yiming Pharmaceuticals Business Overview
11.17.3 Shanghai Soho-Yiming Pharmaceuticals Formulation CDMO Services Introduction
11.17.4 Shanghai Soho-Yiming Pharmaceuticals Revenue in Formulation CDMO Services Business (2018-2023)
11.17.5 Shanghai Soho-Yiming Pharmaceuticals Recent Development
11.18 Chinese Peptide Company
11.18.1 Chinese Peptide Company Company Detail
11.18.2 Chinese Peptide Company Business Overview
11.18.3 Chinese Peptide Company Formulation CDMO Services Introduction
11.18.4 Chinese Peptide Company Revenue in Formulation CDMO Services Business (2018-2023)
11.18.5 Chinese Peptide Company Recent Development
11.19 Ambio Pharmaceuticals
11.19.1 Ambio Pharmaceuticals Company Detail
11.19.2 Ambio Pharmaceuticals Business Overview
11.19.3 Ambio Pharmaceuticals Formulation CDMO Services Introduction
11.19.4 Ambio Pharmaceuticals Revenue in Formulation CDMO Services Business (2018-2023)
11.19.5 Ambio Pharmaceuticals Recent Development
11.20 Zhejiang Peptites Biotech
11.20.1 Zhejiang Peptites Biotech Company Detail
11.20.2 Zhejiang Peptites Biotech Business Overview
11.20.3 Zhejiang Peptites Biotech Formulation CDMO Services Introduction
11.20.4 Zhejiang Peptites Biotech Revenue in Formulation CDMO Services Business (2018-2023)
11.20.5 Zhejiang Peptites Biotech Recent Development
11.21 STA Pharmaceutical
11.21.1 STA Pharmaceutical Company Detail
11.21.2 STA Pharmaceutical Business Overview
11.21.3 STA Pharmaceutical Formulation CDMO Services Introduction
11.21.4 STA Pharmaceutical Revenue in Formulation CDMO Services Business (2018-2023)
11.21.5 STA Pharmaceutical Recent Development
11.22 Zhejiang Langhua Pharmaceutical
11.22.1 Zhejiang Langhua Pharmaceutical Company Detail
11.22.2 Zhejiang Langhua Pharmaceutical Business Overview
11.22.3 Zhejiang Langhua Pharmaceutical Formulation CDMO Services Introduction
11.22.4 Zhejiang Langhua Pharmaceutical Revenue in Formulation CDMO Services Business (2018-2023)
11.22.5 Zhejiang Langhua Pharmaceutical Recent Development
11.23 Viva Biotech
11.23.1 Viva Biotech Company Detail
11.23.2 Viva Biotech Business Overview
11.23.3 Viva Biotech Formulation CDMO Services Introduction
11.23.4 Viva Biotech Revenue in Formulation CDMO Services Business (2018-2023)
11.23.5 Viva Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Formulation CDMO Services Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Small Molecule CDMO
Table 3. Key Players of Macro-molecular CDMO
Table 4. Global Formulation CDMO Services Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 5. Global Formulation CDMO Services Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Formulation CDMO Services Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Formulation CDMO Services Market Share by Region (2018-2023)
Table 8. Global Formulation CDMO Services Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Formulation CDMO Services Market Share by Region (2024-2033)
Table 10. Formulation CDMO Services Market Trends
Table 11. Formulation CDMO Services Market Drivers
Table 12. Formulation CDMO Services Market Challenges
Table 13. Formulation CDMO Services Market Restraints
Table 14. Global Formulation CDMO Services Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Formulation CDMO Services Market Share by Players (2018-2023)
Table 16. Global Top Formulation CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Formulation CDMO Services as of 2022)
Table 17. Ranking of Global Top Formulation CDMO Services Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Formulation CDMO Services Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Formulation CDMO Services Product Solution and Service
Table 21. Date of Enter into Formulation CDMO Services Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Formulation CDMO Services Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Formulation CDMO Services Revenue Market Share by Type (2018-2023)
Table 25. Global Formulation CDMO Services Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Formulation CDMO Services Revenue Market Share by Type (2024-2033)
Table 27. Global Formulation CDMO Services Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Formulation CDMO Services Revenue Market Share by Application (2018-2023)
Table 29. Global Formulation CDMO Services Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Formulation CDMO Services Revenue Market Share by Application (2024-2033)
Table 31. North America Formulation CDMO Services Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 32. North America Formulation CDMO Services Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Formulation CDMO Services Market Size by Country (2024-2033) & (US$ Million)
Table 34. Europe Formulation CDMO Services Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. Europe Formulation CDMO Services Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Formulation CDMO Services Market Size by Country (2024-2033) & (US$ Million)
Table 37. Asia-Pacific Formulation CDMO Services Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 38. Asia-Pacific Formulation CDMO Services Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Formulation CDMO Services Market Size by Region (2024-2033) & (US$ Million)
Table 40. Latin America Formulation CDMO Services Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 41. Latin America Formulation CDMO Services Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Formulation CDMO Services Market Size by Country (2024-2033) & (US$ Million)
Table 43. Middle East & Africa Formulation CDMO Services Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Middle East & Africa Formulation CDMO Services Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Formulation CDMO Services Market Size by Country (2024-2033) & (US$ Million)
Table 46. Medicilon Company Detail
Table 47. Medicilon Business Overview
Table 48. Medicilon Formulation CDMO Services Product
Table 49. Medicilon Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 50. Medicilon Recent Development
Table 51. Gliead Company Detail
Table 52. Gliead Business Overview
Table 53. Gliead Formulation CDMO Services Product
Table 54. Gliead Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 55. Gliead Recent Development
Table 56. Boehringer Ingelheim Company Detail
Table 57. Boehringer Ingelheim Business Overview
Table 58. Boehringer Ingelheim Formulation CDMO Services Product
Table 59. Boehringer Ingelheim Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 60. Boehringer Ingelheim Recent Development
Table 61. Vertex Company Detail
Table 62. Vertex Business Overview
Table 63. Vertex Formulation CDMO Services Product
Table 64. Vertex Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 65. Vertex Recent Development
Table 66. Mirati Therapeutics Company Detail
Table 67. Mirati Therapeutics Business Overview
Table 68. Mirati Therapeutics Formulation CDMO Services Product
Table 69. Mirati Therapeutics Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 70. Mirati Therapeutics Recent Development
Table 71. AMPAC Company Detail
Table 72. AMPAC Business Overview
Table 73. AMPAC Formulation CDMO Services Product
Table 74. AMPAC Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 75. AMPAC Recent Development
Table 76. Pfizer Company Detail
Table 77. Pfizer Business Overview
Table 78. Pfizer Formulation CDMO Services Product
Table 79. Pfizer Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. Polypeptide Company Detail
Table 82. Polypeptide Business Overview
Table 83. Polypeptide Formulation CDMO Services Product
Table 84. Polypeptide Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 85. Polypeptide Recent Development
Table 86. Bachem Company Detail
Table 87. Bachem Business Overview
Table 88. Bachem Formulation CDMO Services Product
Table 89. Bachem Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 90. Bachem Recent Development
Table 91. Merck Company Detail
Table 92. Merck Business Overview
Table 93. Merck Formulation CDMO Services Product
Table 94. Merck Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 95. Merck Recent Development
Table 96. Asymchem Company Detail
Table 97. Asymchem Business Overview
Table 98. Asymchem Formulation CDMO Services Product
Table 99. Asymchem Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 100. Asymchem Recent Development
Table 101. Zhejiang Jiuzhou Pharmaceutical Company Detail
Table 102. Zhejiang Jiuzhou Pharmaceutical Business Overview
Table 103. Zhejiang Jiuzhou Pharmaceutical Formulation CDMO Services Product
Table 104. Zhejiang Jiuzhou Pharmaceutical Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 105. Zhejiang Jiuzhou Pharmaceutical Recent Development
Table 106. Sinopep Company Detail
Table 107. Sinopep Business Overview
Table 108. Sinopep Formulation CDMO Services Product
Table 109. Sinopep Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 110. Sinopep Recent Development
Table 111. Frontier Biotechnologies Company Detail
Table 112. Frontier Biotechnologies Business Overview
Table 113. Frontier Biotechnologies Formulation CDMO Services Product
Table 114. Frontier Biotechnologies Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 115. Frontier Biotechnologies Recent Development
Table 116. JYMed Company Detail
Table 117. JYMed Business Overview
Table 118. JYMed Formulation CDMO Services Product
Table 119. JYMed Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 120. JYMed Recent Development
Table 121. Chengdu Shengnuo Biotechnology Company Detail
Table 122. Chengdu Shengnuo Biotechnology Business Overview
Table 123. Chengdu Shengnuo Biotechnology Formulation CDMO Services Product
Table 124. Chengdu Shengnuo Biotechnology Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 125. Chengdu Shengnuo Biotechnology Recent Development
Table 126. Shanghai Soho-Yiming Pharmaceuticals Company Detail
Table 127. Shanghai Soho-Yiming Pharmaceuticals Business Overview
Table 128. Shanghai Soho-Yiming Pharmaceuticals Formulation CDMO Services Product
Table 129. Shanghai Soho-Yiming Pharmaceuticals Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 130. Shanghai Soho-Yiming Pharmaceuticals Recent Development
Table 131. Chinese Peptide Company Company Detail
Table 132. Chinese Peptide Company Business Overview
Table 133. Chinese Peptide Company Formulation CDMO Services Product
Table 134. Chinese Peptide Company Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 135. Chinese Peptide Company Recent Development
Table 136. Ambio Pharmaceuticals Company Detail
Table 137. Ambio Pharmaceuticals Business Overview
Table 138. Ambio Pharmaceuticals Formulation CDMO Services Product
Table 139. Ambio Pharmaceuticals Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 140. Ambio Pharmaceuticals Recent Development
Table 141. Zhejiang Peptites Biotech Company Detail
Table 142. Zhejiang Peptites Biotech Business Overview
Table 143. Zhejiang Peptites Biotech Formulation CDMO Services Product
Table 144. Zhejiang Peptites Biotech Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 145. Zhejiang Peptites Biotech Recent Development
Table 146. STA Pharmaceutical Company Detail
Table 147. STA Pharmaceutical Business Overview
Table 148. STA Pharmaceutical Formulation CDMO Services Product
Table 149. STA Pharmaceutical Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 150. STA Pharmaceutical Recent Development
Table 151. Zhejiang Langhua Pharmaceutical Company Detail
Table 152. Zhejiang Langhua Pharmaceutical Business Overview
Table 153. Zhejiang Langhua Pharmaceutical Formulation CDMO Services Product
Table 154. Zhejiang Langhua Pharmaceutical Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 155. Zhejiang Langhua Pharmaceutical Recent Development
Table 156. Viva Biotech Company Detail
Table 157. Viva Biotech Business Overview
Table 158. Viva Biotech Formulation CDMO Services Product
Table 159. Viva Biotech Revenue in Formulation CDMO Services Business (2018-2023) & (US$ Million)
Table 160. Viva Biotech Recent Development
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Formulation CDMO Services Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Formulation CDMO Services Market Share by Type: 2022 VS 2033
Figure 3. Small Molecule CDMO Features
Figure 4. Macro-molecular CDMO Features
Figure 5. Global Formulation CDMO Services Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 6. Global Formulation CDMO Services Market Share by Application: 2022 VS 2033
Figure 7. Clinical Application Case Studies
Figure 8. Commercial Production Case Studies
Figure 9. Formulation CDMO Services Report Years Considered
Figure 10. Global Formulation CDMO Services Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 11. Global Formulation CDMO Services Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 12. Global Formulation CDMO Services Market Share by Region: 2022 VS 2033
Figure 13. Global Formulation CDMO Services Market Share by Players in 2022
Figure 14. Global Top Formulation CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Formulation CDMO Services as of 2022)
Figure 15. The Top 10 and 5 Players Market Share by Formulation CDMO Services Revenue in 2022
Figure 16. North America Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 17. North America Formulation CDMO Services Market Share by Country (2018-2033)
Figure 18. United States Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 19. Canada Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. Europe Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Europe Formulation CDMO Services Market Share by Country (2018-2033)
Figure 22. Germany Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. France Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. U.K. Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Italy Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Russia Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Nordic Countries Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Asia-Pacific Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Asia-Pacific Formulation CDMO Services Market Share by Region (2018-2033)
Figure 30. China Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Japan Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. South Korea Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Southeast Asia Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. India Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Australia Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Latin America Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Latin America Formulation CDMO Services Market Share by Country (2018-2033)
Figure 38. Mexico Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Brazil Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Middle East & Africa Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Middle East & Africa Formulation CDMO Services Market Share by Country (2018-2033)
Figure 42. Turkey Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Saudi Arabia Formulation CDMO Services Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Medicilon Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 45. Gliead Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 46. Boehringer Ingelheim Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 47. Vertex Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 48. Mirati Therapeutics Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 49. AMPAC Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 50. Pfizer Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 51. Polypeptide Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 52. Bachem Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 53. Merck Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 54. Asymchem Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 55. Zhejiang Jiuzhou Pharmaceutical Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 56. Sinopep Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 57. Frontier Biotechnologies Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 58. JYMed Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 59. Chengdu Shengnuo Biotechnology Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 60. Shanghai Soho-Yiming Pharmaceuticals Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 61. Chinese Peptide Company Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 62. Ambio Pharmaceuticals Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 63. Zhejiang Peptites Biotech Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 64. STA Pharmaceutical Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 65. Zhejiang Langhua Pharmaceutical Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 66. Viva Biotech Revenue Growth Rate in Formulation CDMO Services Business (2018-2023)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed